Gerards MC, et al. - Researchers undertook a comparison of the effectiveness and safety of add-on treatment with dapagliflozin to placebo in patients with prednisone-induced hyperglycaemia during treatment for acute exacerbation of chronic obstructive pulmonary disease (AECOPD). Treatment with dapagliflozin was discovered to be safe. No variation was observed in the risk of hypoglycaemia compared with placebo. Findings demonstrated that dapagliflozin did not cause better glycaemic control compared with placebo in subjects with prednisone-induced hyperglycaemia during AECOPD.